Menu Close

After three straight years of growth, independent medical review (IMR) activity in California workers’ compensation has finally leveled off. Volume slipped slightly in the first nine months of 2026, while the share of disputes in which IMR physicians side with the original utilization review decision stayed above 90%, according to a November 9, 2026 release from the California Workers’ Compensation Institute (CWCI).

CWCI counted 110,965 IMR decision letters issued from January through September 2026, down 3.1% from the same period in 2025. That is the first decline since IMR volume began climbing back from a historic low in 2022. Even so, this year’s nine-month total remains higher than the comparable totals for every year from 2020 through 2024, so the dip leaves volume well above where it stood just a few years ago. The Institute’s analysis draws on state data covering roughly 1.8 million IMR decision letters issued from 2015 through September 2026.

IMR is the final step for resolving disputes over whether a treatment requested by an injured worker’s doctor is medically necessary. The process was created by Senate Bill 863, the 2012 reform package that overhauled California’s system for resolving medical treatment disputes. When a claims administrator’s utilization review denies or modifies a treatment request under Labor Code § 4610, the worker or the worker’s representative may ask for IMR under Labor Code § 4610.5. The Division of Workers’ Compensation contracts with an independent medical review organization, currently Maximus Federal Services, to conduct the reviews. State regulations (8 CCR § 9792.10.6) generally require a final determination within 30 days of receiving the application and supporting records. Under Labor Code § 4610.6, the Workers’ Compensation Appeals Board may overturn an IMR determination only on narrow grounds, which makes IMR outcomes effectively final in most disputes.

Those outcomes continue to strongly favor the original review decision. CWCI reports that IMR physicians upheld utilization review denials and modifications in 90.2% of 2026 decisions, up slightly from 89.8% in 2025 and consistent with the narrow range seen since 2015. Uphold rates varied by type of service, from a low of 80.8% for evaluation and management services to a high of 95.2% for acupuncture. The uphold rate rose from 86.1% to 88.8% for surgery requests and from 81.3% to 83.1% for psychiatric services.

Prescription drugs remain the largest source of IMR disputes, at 30.8% of decisions, up from 30.5% in 2025. Physical therapy ranked second at 13.2% and injections third at 12.8%.

Within the drug category, the data shows a continued move away from opioid disputes. Opioids fell to 16.7% of prescription drug IMRs, and the share of opioid denials upheld reached an all-time high of 95.7%. Dermatological drugs, the topical creams and similar products often prescribed for pain, rose to a record 25.9% of pharmaceutical IMRs. That is more than double their 12.3% share in 2018, making them the most frequently disputed drug category. Musculoskeletal drugs ranked second at 20.0% and had the highest uphold rate of any drug group, at 98.5%. Anticonvulsants, some of which are prescribed for nerve pain, also hit a record at 10.6% of drug IMRs.

The drug findings come on the heels of other CWCI research tracking prescription cost drivers. Earlier this month, the Institute reported that meloxicam has become the largest source of anti-inflammatory drug spending in California workers’ comp, driven largely by high-cost capsule formulations.

As in prior years, a small group of physicians generates most of the IMR caseload. In the 12 months ending September 2026, the top 10% of requesting physicians, 789 providers, accounted for 84.5% of disputed service requests. The top 1%, just 79 providers, accounted for 41.9%. Ten individual physicians alone accounted for 10.4% of disputed requests decided through IMR, and their requests were upheld at a 90.3% rate, almost exactly the system-wide average. This concentration has been a recurring theme of CWCI’s IMR research and has long fueled debate over whether a relatively small number of high-volume prescribers drives a disproportionate share of medical disputes and the costs of administering them.

The release does not offer an explanation for this year’s decline, and the figures cover only three quarters. CWCI says it will publish full-year 2026 results later, and the more detailed statistics behind the release are available only to CWCI members through the Independent Medical Review section of the Research tab on the CWCI website. Readers looking for longer-term context can consult CWCI’s earlier research update on IMR trends and outcomes from 2015 through 2025.